Ultima Genomics

Ultima Genomics is an emerging disruptor in the next-generation sequencing (NGS) instrument market, challenging the dominance of Illumina with its novel UG200™ Series. The platform leverages innovations from semiconductor manufacturing to offer a significant leap in throughput and cost-effectiveness, targeting large-scale projects in population genomics, oncology, and multi-omics. The company operates a platform-and-partnership business model, selling its sequencers and consumables while fostering an open ecosystem with certified service providers and compatible third-party reagents. As a private company, Ultima is positioned to capture market share by addressing the growing demand for affordable, high-volume genomic data.

Ultima's UG200™ Series is a high-throughput DNA sequencing platform that uses a novel isothermal amplification process (replacing ePCR) and semiconductor-inspired wafer-based design to deliver up to 20B reads per run with improved uniformity and variant calling accuracy.

Ultima Genomics directly challenges Illumina's dominance in the high-throughput sequencing instrument market, particularly targeting the NovaSeq X series. Its main competitive advantages are claimed superior throughput-per-dollar and a smaller instrument footprint. Other competitors include MGI Tech and Pacific Biosciences, which operate in different throughput and application niches.